Photo of Bishal Gyawali taken from qcri.queensu.ca
Feb 14, 2024, 19:39
Bishal Gyawali: A pseudo-innovation for which you get to pay more without any added benefits
Bishal Gyawali, Associate Professor and Medical Oncologist at
“Read the news that NALIRIFOX got approved today by the FDA. Don’t be misled to believe that this represents any innovation. This is a pseudo-innovation for which you get to pay more without any added benefits. We discuss this and other pancreatic cancer treatments in our recent The Lancet Oncology essay.”
Proceed to the essay.
Source: Bishal Gyawali/X